
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <title>Gentamicin Neonatal Dosing Guide</title>
  <style>
    body { font-family: Arial, sans-serif; line-height: 1.6; margin: 2rem; max-width: 900px; }
    table { border-collapse: collapse; width: 100%; margin-top: 1rem; }
    th, td { border: 1px solid #ccc; padding: 0.5rem; text-align: center; }
    th { background-color: #f2f2f2; }
    h2 { margin-top: 2rem; }
  </style>
</head>
<body>

<h1>Gentamicin Neonatal Dosing Guide</h1>

<p><strong>Dosing considerations:</strong> Determination of dosing interval requires consideration of multiple factors including concomitant medications (e.g., ibuprofen, indomethacin), history of birth depression, birth hypoxia/asphyxia, and presence of cyanotic congenital heart disease. Dosage should be individualized based upon serum concentration monitoring.</p>

<p>Impact of extracorporeal membrane oxygenation (ECMO) on neonatal pharmacokinetic parameters is not fully elucidated; optimal dose and frequency not established in ECMO patients. Closely monitor serum concentrations and determine individual dosing needs in these patients.</p>

<h2>General Dosing for Susceptible Infections</h2>

<p>Note: Due to maturational processes, regimens referred to as "extended-interval" in neonates do not typically achieve concentrations that would be expected in older patients. Some dosing is based on tobramycin studies.</p>

<table>
  <thead>
    <tr>
      <th>Gestational Age</th>
      <th>Postnatal Age</th>
      <th>Dosage</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>&lt;30 weeks</td>
      <td>&le;14 days</td>
      <td>5 mg/kg every 48 hours</td>
    </tr>
    <tr>
      <td>&lt;30 weeks</td>
      <td>&ge;15 days</td>
      <td>5 mg/kg every 36 hours</td>
    </tr>
    <tr>
      <td>30–34 weeks</td>
      <td>&le;10 days</td>
      <td>5 mg/kg every 36 hours</td>
    </tr>
    <tr>
      <td>30–34 weeks</td>
      <td>11–60 days</td>
      <td>5 mg/kg every 24 hours</td>
    </tr>
    <tr>
      <td>&ge;35 weeks</td>
      <td>&le;7 days</td>
      <td>4 mg/kg every 24 hours</td>
    </tr>
    <tr>
      <td>&ge;35 weeks</td>
      <td>8–60 days</td>
      <td>5 mg/kg every 24 hours</td>
    </tr>
  </tbody>
</table>

<h2>CNS Infection</h2>
<p><strong>Intraventricular/intrathecal (use a preservative-free preparation):</strong> 1 mg/day</p>
<p><em>Note:</em> A trial evaluating routine use of a higher dose (2.5 mg/day) reported a higher mortality rate.</p>

<h2>Renal Impairment Adjustment</h2>
<p>Consider single-dose administration with serum concentration monitoring instead of scheduled dosing in patients with urine output &lt;1 mL/kg/hour or if serum creatinine significantly increases from baseline.</p>

</body>
</html>
